Rigel Pharmaceuticals, Inc.
RIGL Healthcare Biotechnology
Rigel Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $294.3 million, up 64.1% from fiscal 2024. In the quarter to June 2026, revenue fell 22.6%, EPS fell 72.1%, free cash flow fell 230.0% and total debt fell 66.6%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow RIGL
A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income |
367.02 | 17.49 | (25.09) | (58.57) | (17.91) | (29.74) | (66.89) | (70.48) | (77.99) | (69.22) |
Depreciation & Amortization |
1.27 | 1.52 | 0.76 | 0.94 | 1.45 | 0.58 | (0.39) | (0.17) | 0.12 | 1.06 |
Non Cash Items (Other) |
(273.12) | 12.31 | 9.07 | 12.93 | 12.63 | 7.30 | 9.12 | 7.70 | 5.75 | 8.06 |
Accounts Receivable Change |
(10.15) | (11.06) | 9.77 | (24.85) | 0.50 | (5.86) | (6.03) | (4.08) | — | 0.20 |
Change in inventories |
(5.63) | 0.76 | 1.17 | (2.38) | (4.87) | (0.13) | (0.37) | (0.84) | — | — |
Accounts Payable Change |
3.85 | (3.80) | (0.37) | 3.79 | 0.04 | (0.33) | (2.24) | 3.76 | (2.95) | 2.80 |
Change in payables and accrued liability |
3.23 | 2.02 | (4.38) | (2.79) | 6.57 | 1.02 | 1.19 | 4.90 | 4.36 | (1.34) |
Change in other assets and liabilities |
(10.81) | 12.23 | 3.33 | (2.82) | 7.48 | (25.02) | 24.11 | 0.39 | (6.84) | (17.46) |
Operating Cash Flow |
75.66 | 31.47 | (5.74) | (73.76) | 5.88 | (52.18) | (41.51) | (58.83) | (77.56) | (75.89) |
Capital expenditures |
— | 0.06 | 0.26 | 0.44 | (0.63) | (1.26) | (1.45) | (1.11) | 0.57 | (0.72) |
Change in intangibles (net) |
— | (0.36) | (15.00) | — | — | — | — | — | — | — |
Short Term Investments Change (Net) |
(92.36) | 4.43 | 10.44 | 72.33 | (79.41) | 48.73 | (22.20) | 26.07 | (20.04) | 25.60 |
Investing cash flow |
(92.36) | 4.13 | (4.30) | 72.78 | (80.04) | 47.47 | (23.66) | 24.96 | (19.47) | 24.88 |
Repayment/Issuance of Debt (Net) |
(7.50) | — | 19.95 | 19.54 | 57.90 | 9.98 | 9.79 | — | — | — |
Equity Repurchase (Common, Net) |
8.10 | 1.96 | 1.05 | 2.12 | 4.78 | 2.60 | 1.58 | 71.89 | 117.69 | 25.18 |
Other financial activities |
— | (13.60) | 17.32 | (15.12) | 57.90 | 7.18 | 8.04 | 6.94 | 5.40 | 8.18 |
Financing cash flow |
0.60 | (11.64) | 18.37 | 6.55 | 62.68 | 12.57 | 11.37 | 71.89 | 117.69 | 25.18 |
Change in Cash |
(16.11) | 23.96 | 8.33 | 5.57 | (11.48) | 7.85 | (53.80) | 38.03 | 20.66 | (25.82) |
Beginning Cash |
56.75 | 32.79 | 24.46 | 18.89 | 30.37 | 22.52 | 76.32 | 38.29 | 17.63 | 43.46 |
Ending Cash |
40.64 | 56.75 | 32.79 | 24.46 | 18.89 | 30.37 | 22.52 | 76.32 | 38.29 | 17.63 |
Stock Based Compensation |
12.71 | 12.39 | 8.81 | 12.39 | 9.49 | 7.30 | 9.12 | 7.70 | 5.99 | 7.33 |
Dividends Paid (Common) |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash/Marketcap |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Assets Liabilities Change (Total) |
(19.51) | 0.15 | 9.52 | (29.05) | 9.72 | (30.32) | 16.66 | 4.12 | (5.43) | (15.79) |
Investments Change (Net) |
(92.36) | 4.43 | 10.44 | 72.33 | (79.41) | 48.73 | (22.20) | 26.07 | (20.04) | 25.60 |
Issuance/Purchase of Shares |
8.10 | 1.96 | 1.05 | 2.12 | 4.78 | 2.60 | 1.58 | 71.89 | 117.69 | 25.18 |
| Other line items | ||||||||||
Revenue per Employee |
1.69 | 1.09 | 0.80 | 0.78 | 0.90 | 0.64 | 0.36 | 0.28 | 0.04 | 0.26 |